- the company has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company’s Cloudbreak:registered: influenza (antiviral) program
- Data supporting the selection will be presented today in an oral session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
The ultimate goal is to achieve influenza relief for an entire year through the application of their technology.
Initial results are being shared at the 2019 ECCMID Conference this week.
What do you think of this approach? There are a couple of companies attempting to use oncological ADC principles for non-oncology therapies. Dyne Therapeutics comes to mind. Is this the next stage of ADC development, or a niche off-shoot which is unlikely to gain major traction?